Headlines about China Cord Blood (NYSE:CO) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. China Cord Blood earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.7942200142136 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of China Cord Blood (NYSE CO) opened at $11.01 on Friday. The stock has a market cap of $1,323.03, a P/E ratio of 31.34 and a beta of 0.89. China Cord Blood has a fifty-two week low of $4.27 and a fifty-two week high of $14.95.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/china-cord-blood-co-getting-somewhat-positive-news-coverage-report-finds/1738819.html.

About China Cord Blood

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Insider Buying and Selling by Quarter for China Cord Blood (NYSE:CO)

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.